Highlights
In a large single-center series of 850 patients with acute type A aortic dissection (ATAAD), frozen elephant trunk plus total arch replacement (FET + TAR) achieved an operative mortality of 8.4% and acceptable neurologic complication rates despite the complexity of the procedure.
Among early survivors with near-complete follow-up over a mean of 12.5 years, estimated 20-year survival was 70.0% and freedom from reoperation was 85.4%, supporting the durability of this extensive upfront strategy.
Compared with propensity-matched hemiarch repair, FET showed similar operative mortality but lower rates of late adverse events, including death, reoperation, and distal aortic dilation, with superior 20-year freedom from late adverse events.
Late mortality was strongly associated with preoperative end-organ ischemia, particularly visceral ischemia, underscoring that the biology and presentation of dissection still shape outcomes even after technically successful repair.
Background and Clinical Context
ATAAD remains one of the most time-sensitive emergencies in cardiovascular surgery. Mortality rises rapidly without treatment, and even after successful surgery patients remain at risk for persistent false-lumen perfusion, distal aneurysmal degeneration, late reintervention, stroke, renal dysfunction, and death. Historically, many centers favored limited proximal repair or hemiarch replacement to reduce operative complexity in unstable patients. However, that conservative approach can leave substantial residual disease in the arch and descending thoracic aorta.
Over the past two decades, some high-volume aortic centers have moved toward a more aggressive index operation. The FET technique combines open arch replacement with antegrade deployment of a stented graft into the proximal descending thoracic aorta. In theory, this offers several advantages: resection of arch intimal tears, expansion of the true lumen, promotion of distal aortic remodeling, improved treatment of malperfusion, and reduction in later distal aortic dilation. The tradeoff is a longer, technically more demanding operation with potential added risks, especially neurologic injury and spinal cord ischemia.
That tension between immediate operative risk and long-term aortic benefit is central to decision-making in ATAAD. The present study by Ma and colleagues is clinically important because it reports long-term outcomes across two decades, a duration rarely available for modern FET series. It also attempts to address the practical comparison surgeons face at the operating table: whether the extended arch strategy truly outperforms hemiarch repair over time.
Study Design
Population and Setting
This was a retrospective single-center study of 850 consecutive patients with ATAAD who underwent FET + TAR between April 2003 and December 2014. The mean age was 46.5 ± 10.7 years, notably younger than many Western ATAAD cohorts, and 169 patients (19.9%) were women. Malperfusion syndrome was present in 136 patients (16.0%). Concomitant aortic root or valve procedures were required in 456 patients (53.6%), reflecting substantial proximal disease complexity.
Intervention
The operative strategy consisted of total arch replacement combined with frozen elephant trunk implantation. This approach is intended to address both the proximal emergency and the downstream aortic pathology in a single stage. Because ATAAD anatomy is heterogeneous, patient selection and operative execution likely reflected institutional protocols and surgeon expertise developed over a long learning curve.
Comparator
For comparative analysis, the investigators matched FET patients to a hemiarch repair cohort using propensity methods, yielding 72 matched pairs. This comparison is clinically relevant, although modest in size relative to the overall FET series.
Endpoints
The main outcomes included operative mortality, major postoperative complications, long-term survival, late death, reoperation, and a composite of late adverse events (LAE) that included death, reoperation, and distal aortic dilation. Follow-up completeness was excellent at 99.2% among operative survivors, with a mean duration of 12.5 ± 4.0 years and a range extending to 22 years.
Key Results
Early Outcomes
Operative mortality was 8.4% (71 of 850), a figure that should be interpreted in the context of emergency surgery for a disease with high baseline lethality and the extensive nature of FET + TAR. Major complications were reported as follows: spinal cord injury in 2.5% (21 of 850), stroke in 3.5% (30 of 850), re-exploration for bleeding in 5.6% (48 of 850), and acute kidney injury in 8.7% (74 of 850).
These early results are notable because total arch replacement plus FET is often perceived as carrying prohibitive perioperative risk in the acute dissection setting. In this high-volume environment, neurologic complication rates were relatively contained. The spinal cord injury rate deserves particular attention: while low in absolute terms, it remains a uniquely important concern for extended distal repair and is one of the major factors limiting broader adoption of the technique.
Long-Term Survival and Reintervention
Among 779 operative survivors, 773 had complete follow-up. There were 153 late deaths and 90 reoperations. The median time to late death was 7.5 years, and the median time to reoperation was 5.2 years, indicating that clinically important downstream events continue to accrue years after the index surgery.
Estimated survival at 20 years was 70.0% and freedom from reoperation was 85.4% (95% confidence interval [CI], 65.8% to 74.0% and 80.1% to 89.4%, respectively). For a disease as lethal and structurally complex as ATAAD, these figures suggest that an aggressive initial repair can deliver durable benefit in appropriately treated patients.
The competing-risks analysis adds nuance beyond standard Kaplan-Meier estimates. At 15 years, the incidences were 25% for death, 13% for reoperation, and 62% for reoperation-free survival. This is clinically useful because death and reoperation are competing events; ignoring that interaction can overstate the probability of later interventions.
Risk Factors for Late Death
Two preoperative ischemic complications emerged as significant predictors of late death: cerebrovascular accident (hazard ratio [HR] 2.34; P = .031) and visceral ischemia (HR 4.12; P = .005). These findings are biologically plausible. End-organ malperfusion is not just an operative challenge; it is also a marker of more extensive dissection, greater physiologic insult, and potentially irreversible organ injury that can shape long-term survival even after a technically successful repair.
The especially strong association with visceral ischemia is important for front-line decision-making. It reinforces the idea that ATAAD is not a single disease entity but a spectrum of presentations, and that preoperative instability and ischemic burden remain central determinants of prognosis. Extended arch repair may improve the anatomy, but it may not fully erase the consequences of severe systemic malperfusion at presentation.
Comparison With Hemiarch Repair
In the propensity-matched analysis, operative mortality was similar between FET and hemiarch repair (6.9% vs 4.2%, P = .719). Although the study was not powered to prove equivalence, the absence of a significant mortality penalty is a key practical finding. If an extended repair can be performed without materially worsening early survival, its long-term advantages become highly relevant.
FET was associated with a lower incidence of LAE than hemiarch repair (16.4% vs 33.8%, P = .048). Freedom from LAE at 20 years was significantly higher with FET: 78.0% versus 45.6% (95% CI, 58.8% to 89.0% vs 27.7% to 61.8%; P = .042). Because this composite included death, reoperation, and distal aortic dilation, the result suggests that the benefits of FET extend beyond merely reducing technical reintervention. It appears to improve the long-term trajectory of the residual dissected aorta.
This aligns with the conceptual rationale for FET. By sealing proximal descending thoracic re-entry sites and promoting false-lumen thrombosis, the technique may prevent later enlargement of the distal aorta and reduce the need for staged procedures. In ATAAD, where residual patent false lumen has long been linked to adverse remodeling, that mechanism carries major clinical appeal.
Clinical Interpretation
This study supports a growing view that in selected patients and experienced centers, ATAAD should not always be treated with the shortest possible operation. For many years, the dominant logic favored limiting arch intervention to avoid prolonging circulatory arrest and cerebral perfusion times. Ma and colleagues provide long-range evidence that a more definitive index repair can pay dividends over decades.
The central clinical message is not that FET should replace hemiarch repair universally. Rather, it suggests that the tradeoff has shifted. In expert hands, the early hazard of FET + TAR may be acceptable, while the downstream benefit appears meaningful. This is especially relevant in younger patients, in those with primary arch tears, distal malperfusion, arch aneurysmal involvement, connective tissue disease, or a large residual dissected descending aorta at risk for later enlargement.
The relatively young mean age of 46.5 years strengthens the case for durability. A 40- or 50-year-old patient surviving ATAAD may otherwise face decades of surveillance and cumulative reintervention risk if residual arch or descending false lumen remains patent. An operation that reduces late aortic events is particularly attractive in that population. At the same time, these demographics may limit direct extrapolation to older populations commonly seen in North America and Europe, where frailty, comorbidity, and competing causes of death may alter the balance between extensive and conservative repair.
Strengths of the Study
The study has several major strengths. First, the sample size is large for a highly specialized emergency operation. Second, follow-up completeness was excellent, which greatly improves confidence in long-term outcome estimates. Third, the observation period is unusually long, extending to 22 years, and therefore captures the time horizon over which distal aortic pathology becomes clinically important. Fourth, the matched comparison with hemiarch repair addresses a question of direct surgical relevance.
Just as importantly, the study reports both early and late events. In aortic surgery, short-term safety alone can be misleading, while long-term durability alone can obscure the price paid in the operating room. Presenting both allows a more balanced assessment of value.
Limitations and Cautions
Despite its importance, the study should not be read as definitive proof that FET is superior for all ATAAD presentations. It is retrospective and single-center, with all the usual limitations of selection bias, temporal changes in practice, and center-specific expertise. A 20-year experience inevitably includes evolution in cerebral protection, distal perfusion strategy, critical care, imaging, and graft technology. Some outcome improvements may reflect those advances as much as the operation itself.
The propensity-matched comparator is relatively small at 72 pairs, which limits precision and increases the chance of residual confounding. Surgeons may also have selected hemiarch repair for anatomically or physiologically different patients in ways that are difficult to fully capture statistically. Unmeasured differences in dissection anatomy, instability, tear location, or surgeon judgment could influence both treatment choice and long-term outcome.
Generalizability is another concern. This was a high-volume center with deep experience in TAR and FET, and results may not be reproducible in lower-volume settings. ATAAD outcomes are known to be volume-sensitive. An operation that is reasonable in a dedicated aortic program may not deliver the same risk-benefit profile where institutional expertise, perfusion protocols, and postoperative rescue systems are less mature.
Finally, the younger age profile deserves emphasis. Whether similar long-term advantages justify the same upfront complexity in substantially older patients remains uncertain. For a frail 75-year-old with isolated ascending and proximal arch pathology, hemiarch repair may still be the more appropriate operation.
Relationship to Current Practice and Guidelines
Contemporary guidelines generally support individualized arch management in ATAAD, recommending a more extensive repair when there is an arch intimal tear, aneurysmal arch disease, distal malperfusion, or anatomy likely to leave hazardous residual disease after limited repair. This study reinforces that framework. It does not argue for indiscriminate aggressiveness; it argues that extensive repair can be justified when anatomy and center expertise align.
The findings also fit with prior observational literature showing that residual patent false lumen after standard repair is associated with distal aortic enlargement and late reintervention. The present report extends that narrative by showing very long-term durability after an FET-based approach. In doing so, it supports the concept of using the index operation not only to save the patient today, but also to reshape the patient’s long-term aortic future.
Practical Implications for Clinicians
For surgeons and multidisciplinary aortic teams, the most actionable message is that FET + TAR should be considered a durable and defensible strategy for selected ATAAD patients, particularly at centers with established expertise. Patients who are younger, have arch or proximal descending involvement, present with malperfusion, or are judged likely to need downstream intervention may derive the greatest long-term benefit.
For intensivists and cardiologists involved in follow-up, the study is a reminder that ATAAD remains a chronic disease even after successful emergency repair. Long-term imaging surveillance is essential, and preoperative ischemic complications such as stroke and visceral malperfusion identify patients at elevated late mortality risk who may warrant especially close multidisciplinary follow-up.
For health systems, the data support regionalization of complex acute aortic surgery. If the benefits of FET depend heavily on surgical experience and perioperative infrastructure, concentrating such care in specialized centers may be one of the most effective ways to improve both early and late outcomes.
Conclusion
Ma and colleagues present one of the most informative long-term datasets to date on FET + TAR for ATAAD. In 850 patients treated over two decades, the technique produced acceptable early mortality and neurologic morbidity, while delivering durable long-term survival and high freedom from reoperation. In matched comparison, FET achieved similar operative mortality to hemiarch repair but lower rates of late adverse events, including death, reoperation, and distal aortic dilation.
The study strengthens the case for extended arch repair in selected ATAAD patients, especially when performed in experienced aortic centers. Its most important contribution is not simply that FET works, but that its benefits remain visible over decades. That said, patient selection, institutional expertise, and operative judgment remain crucial. The future challenge is to define more precisely which ATAAD phenotypes benefit most from extensive first-stage repair, and how to make those outcomes reproducible across broader practice settings.
Funding and ClinicalTrials.gov
Funding information and ClinicalTrials.gov registration were not reported in the abstract provided. As an observational surgical series spanning 2003 to 2014, the study may not have required prospective trial registration, but readers should consult the full article for detailed disclosures and funding statements.
References
1. Ma WG, Chen Y, Chen SW, Zhang W, Zheng J, Li QG, Lu L, Zhu JM, Piffaretti G, Elefteriades JA, Sun LZ. Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades. European Heart Journal. 2026;47(20):2452-2465. PMID: 41614598.
2. Isselbacher EM, Preventza O, Hamilton Black J 3rd, Augoustides JG, Beck AW, Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Journal of the American College of Cardiology. 2022;80(24):e223-e393.
3. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. European Heart Journal. 2014;35(41):2873-2926.
4. Sun L, Qi R, Zhu J, Liu Y, Zheng J. Total arch replacement combined with stented elephant trunk implantation: a new “standard” therapy for type A dissection involving repair of the aortic arch? Circulation. 2011;123(9):971-978.
